Benzinga | Nov 30, 2021 04:43PM EST

Jefferies Upgrades Ayala Pharmaceuticals to Buy, Raises Price Target to $17

Jefferies analyst Maury Raycroft upgrades Ayala Pharmaceuticals (NASDAQ:AYLA) from Hold to Buy and raises the price target from $12 to $17.